JAK2 V617F mutations in human cancer cell lines and primary hematopoietic cells
. | Total . | V617F . |
|---|---|---|
| Hematologic | ||
| Cell lines | 132 | 2 |
| AML | 25 | 2 |
| CML | 10 | 0 |
| ALL | 37 | 0 |
| Lymphoma | 42 | 0 |
| Myeloma | 14 | 0 |
| Other* | 4 | 0 |
| Primary cells | 211 | 7 |
| AML | 90 | 5 |
| MDS | 20 | 1 |
| CML | 91 | 1 |
| CMML | 5 | 0 |
| CLL | 5 | 0 |
| Nonhematologic | ||
| Cell lines | 486 | 0 |
| Bladder | 15 | 0 |
| Bone | 14 | 0 |
| Brain | 15 | 0 |
| Breast | 27 | 0 |
| Colorectal | 41 | 0 |
| Glioma | 25 | 0 |
| Kidney | 10 | 0 |
| Liver | 10 | 0 |
| Lung | 121 | 0 |
| Neuroblastoma | 15 | 0 |
| Esophagus | 12 | 0 |
| Ovary | 17 | 0 |
| Pancreas | 13 | 0 |
| Skin | 36 | 0 |
| Stomach | 21 | 0 |
| Uterus | 10 | 0 |
| Other† | 84 | 0 |
. | Total . | V617F . |
|---|---|---|
| Hematologic | ||
| Cell lines | 132 | 2 |
| AML | 25 | 2 |
| CML | 10 | 0 |
| ALL | 37 | 0 |
| Lymphoma | 42 | 0 |
| Myeloma | 14 | 0 |
| Other* | 4 | 0 |
| Primary cells | 211 | 7 |
| AML | 90 | 5 |
| MDS | 20 | 1 |
| CML | 91 | 1 |
| CMML | 5 | 0 |
| CLL | 5 | 0 |
| Nonhematologic | ||
| Cell lines | 486 | 0 |
| Bladder | 15 | 0 |
| Bone | 14 | 0 |
| Brain | 15 | 0 |
| Breast | 27 | 0 |
| Colorectal | 41 | 0 |
| Glioma | 25 | 0 |
| Kidney | 10 | 0 |
| Liver | 10 | 0 |
| Lung | 121 | 0 |
| Neuroblastoma | 15 | 0 |
| Esophagus | 12 | 0 |
| Ovary | 17 | 0 |
| Pancreas | 13 | 0 |
| Skin | 36 | 0 |
| Stomach | 21 | 0 |
| Uterus | 10 | 0 |
| Other† | 84 | 0 |
ALL indicates acute lymphoblastic leukemia; CMML, chronic myelomonocytic leukemia; MDS, myelodysplasia; and CLL, chronic lymphocytic leukemia.
Chronic B-cell leukemia (3), refractory anemia (1).
Adrenal (6), bile duct (3), cervix (7), cornea (1), head/neck (7), intestine (2), muscle (1), neuroblastoma (8), placenta (3), pleura (5), primitive neuroectodermal tumor (5), prostate (1), respiratory tract (3), retina (1), rhabdomyosarcoma (6), synovium (1), testis (4), thyroid (8), tongue (6), ureter (4), and vulva (2).